Keyphrases
Roflumilast
33%
Cognition Enhancement
33%
Telephone-based
33%
Headroom
33%
Nootropic
33%
Clinic Population
33%
Automated Speech Analysis
33%
Neurocognitive Disorders
33%
Early Diagnostics
33%
Linguistic Analysis
33%
Speech Analysis
33%
Verbal Memory
33%
Memory Feature
33%
Verbal Learning Task
33%
Conceptual Phase
33%
Mild Alzheimer's Disease
33%
Language Features
33%
Juvenile Form
25%
Semantic Verbal Fluency
22%
Automatic Speech Recognition
22%
Phosphodiesterase-4 (PDE4)
22%
Linguistic Features
16%
Test Tasks
16%
Dementia Onset
13%
Screening Algorithm
13%
Phosphodiesterase Inhibitors
13%
Immediate Recall
11%
Word Count
11%
Delayed Recall
11%
Clinical Dementia Rating
11%
Face-to-face Assessment
9%
Brain Formation
8%
Neurodevelopmental Model
8%
Two-dimensional Cell Culture
8%
Corticogenesis
8%
Escapers
8%
Seizure Episode
8%
Recessive mutation
8%
Psychiatric Conditions
8%
Pediatric Neurodegeneration
8%
Disease Signature
8%
Mobile Speech
8%
Manual Scoring
8%
Two-way Crossover
6%
Verbal Learning Test
6%
Simple Reaction Time
6%
Trail Making Test
6%
Cognitive Measures
6%
Learning Tests
6%
Digit-symbol-substitution Task
6%
Neuroscience
Mild Cognitive Impairment
100%
Synapse
33%
Likert Scale
33%
Organoid
33%
Cognitive Tests
33%
Speech Recognition
33%
Subjective Cognitive Decline
33%
Verification and Validation
33%
Luteolin
33%
Roflumilast
33%
Neuropsychiatric Symptom
33%
Clinical Dementia Rating
22%
Phosphodiesterase
22%
Synapse Formation
16%
Phosphodiesterase Inhibitor
13%
Forskolin
11%
Beta-Glucuronidase
11%
Phosphodiesterase-4 Inhibitor
11%
Brain Development
8%
Stem Cell
8%
Neurodegeneration
8%
Transcriptome
8%
In Vitro
8%
Cell Line
8%
CRISPR
8%
Mental Disorder
8%
Cell Culture
8%
Synaptic Transmission
8%
Event-Related Potential
6%
Alzheimer's Disease
6%
Medicine and Dentistry
Mild Cognitive Impairment
44%
Roflumilast
33%
Biological Marker
33%
Phosphodiesterase IV Inhibitor
33%
Cognitive Defect
27%
Quality Adjusted Life Year
13%
Health Care Cost
13%
Phosphodiesterase Inhibitor
13%
Alzheimer's Disease
11%
Verbal Memory
6%
Learning Test
6%
Relative Risk Reduction
6%
Primary Health Care
6%
Primary Outcome
6%
Verbal Learning
6%
Phosphodiesterase
6%
Regulatory Affairs
6%
Medical Ethics
6%
Clinical Trial
5%
Nausea
5%
Antiinflammatory Agent
5%
Apoplexy
5%
Antiinflammatory Activity
5%
Social Health
5%
Quality of Life
5%
Disease
5%
Central Nervous System Disease
5%
Adverse Effect
5%
Nervous System Disorder
5%
Patient Experience
5%
Treatment Option
5%
Therapeutic Window
5%
Clinical Study
5%
Drug Effect
5%
